Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063534 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29980432 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31013228 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL20450592 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL9989977 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL23200433 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895588 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31284330 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895429 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29887767 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503730-B2 | Detectable nucleotide analogues | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025054459-A1 | RNAI OLIGONUCLEOTIDE CONJUGATES | DICERNA PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240376536-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-04 | — | — | US | disclosed |
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4308110-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | Purdue Research Foundation (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230390406-A1 | Star Polymer Drug Conjugates | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| EP-4228701-A1 | STAR POLYMER DRUG CONJUGATES | Vaccitech North America, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2022197567-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022086853-A1 | STAR POLYMER DRUG CONJUGATES | AVIDEA TECHNOLOGIES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11959137-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | KMT2A 1610/4885EPHX2 2228/4885LMNA 984/4885 |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | KMT2A 588/4885EPHX2 3708/4885LMNA 3368/4885 |
| US-20250236911-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | KMT2A 1553/4885EPHX2 1712/4885LMNA 1088/4885 |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | KMT2A 3562/4885EPHX2 1611/4885LMNA 337/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | KMT2A 1742/4885EPHX2 1792/4885LMNA 1084/4885 |
| US-20240376536-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | KMT2A 1553/4885EPHX2 1712/4885LMNA 1088/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | KMT2A 4193/4885EPHX2 2557/4885LMNA 1909/4885 |
| US-11999999-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | KMT2A 1610/4885EPHX2 2228/4885LMNA 984/4885 |
| US-12006540-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | KMT2A 1610/4885EPHX2 2228/4885LMNA 984/4885 |
| US-20230390406-A1 | Star Polymer Drug Conjugates | CCND3, CCND2, DRD3 | KMT2A 2617/4885EPHX2 2473/4885LMNA 1287/4885 |
| US-12503730-B2 | Detectable nucleotide analogues | NT5C3B, NUDT1, RNGTT | KMT2A 3544/4885EPHX2 2758/4885LMNA 417/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | KMT2A 1610/4885EPHX2 2228/4885LMNA 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.